Late introduction of new guidance from the commission risks detrimentally affecting investors during upcoming proxy season.
A selection of the major stories impacting ESG investors, in five easy pieces.
Donald Trump’s decision to repeal existing measures unlikely to dissuade investors from engaging with pharmaceutical companies.
Investors face mounting technology risks, as policymakers urged to agree global governance framework ahead of AI summit in February.
While steps taken by some US companies have unsettled investors, “substantiative” changes to DEI policies remain few and far between.
Reducing number of votes would enhance their strategic value, says a recent report from investment research institute FCLTGlobal.
Commission’s decision to exclude first corporate lobbying shareholder resolution in more than a decade has raised concerns for investors.
Shareholder resolution warns of value erosion, calls for increased transparency of strategy alignment with climate goals.
Investors intend to step up efforts to hold asset managers to account in 2025, while also pushing back against DCSS and other...
US SIF warns of future infringements on American shareholder rights, but expects “muted” political impact on 2025 proxy season.
Subscribe to our free weekly newsletter below and never miss a story.